Deep Venous Thrombosis Clinical Trial
Official title:
Evaluation of Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in the Surgical Treatment of Colorectal Cancer
The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical practice. However, the use of this medication can have a financial impact on the patient and the parenteral presentation itself is associated with pain at the application site, which can make it difficult for patients to adhere.
There are already robust studies in the literature demonstrating the efficacy and safety of using Rivaroxaban 10mg once a day in the prevention of deep vein thrombosis of the lower limbs in patients undergoing orthopedic knee and hip surgeries.1,2,3 Although there are already trials demonstrating the safety and efficacy of the use of rivaroxaban in the treatment of DVT and venous thromboembolism in cancer patients, there is a lack in the literature, to date, of studies on the efficacy and safety of prophylaxis with Ribaroxaban for DVT of the lower limbs in the post-operative period. operative of colorectal cancer surgeries, both open surgeries and videolaparoscopic surgeries.4 There are robust studies in the literature, with about 3645 patients undergoing colorectal cancer surgery, reporting a VTE incidence of about 0.85%. .OBJECTIVE To determine the efficacy and safety of chemoprophylaxis for DVT with Rivaroxaban in patients undergoing surgical treatment of colorectal cancer. Primary objective: prevention of DVT and VTE in patients after colorectal surgery. Secondary objective: rates of bleeding and adverse events in patients undergoing anticoagulant use. METHOD This is a prospective, observational cohort of patients undergoing surgical treatment for colorectal cancer at the Digestive System and Coloproctology Surgery service at Hospital do Servidor Público Estadual de São Paulo. Patients undergoing chemoprophylaxis with enoxaparin and rivaroxaban to prevent lower limb DVT after surgical treatment of colorectal cancer will be included. In the immediate postoperative period, they will be submitted to chemoprophylaxis with Enoxaparin 40mg subcutaneously 1x/day for 24 hours up to a maximum of 7 days, depending on the release of the diet and the need for a new surgical approach, and at hospital discharge, Rivaroxaban 10mg orally 1x/day will be prescribed until complete 28 days of prophylactic anticoagulation after surgery. Before surgery and after the last dose of chemoprophylaxis, patients will be evaluated with venous USG-Doppler of the lower limbs, in order to detect any possibility of asymptomatic deep vein thrombosis. In addition, 1 week after hospital discharge, patients will be evaluated for symptoms related to the lower limbs in a return visit, as well as any bleeding resulting from the use of drugs for DVT chemoprophylaxis (Table 1). For the diagnosis of DVT we will use clinical and laboratory data and especially venous Doppler ultrasound. The main ultrasound data used for the diagnosis of DVT are vessel incompressibility and lack of flow in the analyzed vessels.5,6 Venous Doppler US will be performed by an examiner blinded to the treatment received by the patient, with compression measurements in the common femoral veins, superficial in the middle third and popliteal vein. The evaluation of venous recanalization will be through verification of total, partial or absent venous flow. In addition, the presence of venous reflux and its degree will be quantified. Diagnostic criteria for acute DVT on Doppler: absence or decrease in venous compression; visible thrombus; increase in venous diameter; no increase in venous diameter with Valsalva; valve immobility; loss of respiratory phasicity; absence or decrease in spontaneous venous flow. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT02889562 -
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
|
Phase 2/Phase 3 | |
Completed |
NCT00812370 -
The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids
|
Phase 1 | |
Completed |
NCT01333618 -
Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter
|
N/A | |
Completed |
NCT02552420 -
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism
|
Phase 2/Phase 3 | |
Completed |
NCT00178789 -
Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis
|
Phase 1/Phase 2 | |
Completed |
NCT03251963 -
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
|
Phase 2 | |
Completed |
NCT03286985 -
The Prevalence and Incidence of DVT in General ICU
|
||
Completed |
NCT04414332 -
Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
|
||
Completed |
NCT02211326 -
Genotype-guided Warfarin Individualized Treatment
|
N/A | |
Completed |
NCT03296280 -
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
|
||
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Completed |
NCT00628576 -
Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
|
Phase 3 | |
Completed |
NCT04979026 -
Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement
|
N/A | |
Active, not recruiting |
NCT02318472 -
Early Mobilization After Achilles Tendon Rupture
|
N/A | |
Completed |
NCT01221805 -
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
|
Phase 4 | |
Recruiting |
NCT03740633 -
Functional Training for the Prevention of Deep Venous Thrombosis
|
Phase 3 | |
Completed |
NCT03707665 -
Deep Venous Thrombosis Screening in the ICU by Nurses
|
||
Recruiting |
NCT05171049 -
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
|
Phase 3 | |
Terminated |
NCT01573169 -
PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients
|
Phase 3 |